Search

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To describe demographic, clinical and physiological characteristics, treatment between first-episode major depressive disorder (MDD), and relapse MDD, and to explore characteristics of relapse MDD. Methods: Totally 858 patients who met the diagnostic criteria for depression of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5),, were included by using the Mini International Neuropsychiatric Interview (MINI), Clinician-Rated Dimensions of Psychosis Symptom Severity, and Hamilton Depression Scale etc. Among them, 529 (58. 6%), were first-episode depression and 329 (36. 0%), were relapsed. The differences of demographic characteristics, clinical and physiological characteristics, treatment were compared by χ2 test and Kruskal-Wallis rank sum test. Multivariate logistic regression was used to explore the characteristics of MDD recurrence. Results: Compared to first-episode MDD, relapse MDD had more comorbidity (OR=2. 11, 95% Cl: 1. 00-4. 44),, more days out of role (OR=1. 26, 95% CI: 1. 01-1. 56), more history of using psychiatric drug more than one month (OR=1. 41, 95% Cl: 1. 02-1. 97), and electroconvulsive therapy (OR=3. 23, 95% Cl: 1. 42-7. 36),, and higher waist-hip ratio (OR=33. 88, 95% Cl: 2. 88-399. 32), . Conclusion: Relapse MDD has positive association with comorbidity of mental disorders, out of role, and higher waist-hip ratio. [ABSTRACT FROM AUTHOR]

Copyright of China Brewing is the property of China Brewing Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Food Safety & Quality is the property of Journal of Food Safety & Quality Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Food Research & Development is the property of Food Research & Development Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Food Safety & Quality is the property of Journal of Food Safety & Quality Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of China Brewing is the property of China Brewing Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the effects of mesalazine on serum levels of CRP, IL-10 and TNF-α in of patients with ulcerative colitis. Methods: 120 patients with ulcerative colitis were randomly divided into the experimental group and the control group, with 60 cases in each group. The patients in the control group were treated with sulfasalazine enteric-coated tablets, while the patients in the experimental group were treated with mesalazine enteric-coated tablets. Then serum levels of C- reactive protein (CRP), tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10), and clinical efficiency and safety in the two groups were observed and compared before and after the treatment. Results: Compared with before treatment, the serum levels of CRP and TNF-α decreased, while the levels ofIL-10 increased in the two groups after treatment, and the differences were statistically significant (P<0.05); Compared with the control group, the serum levels of CRP and TNF-α were lower, and the IL-10 was higher in experimental group, and the differences were statistically significant (P<0.05); Compared with the control group, the clinical effective rate in the experimental group were higher, while the incidence of adverse reactions was lower, and the differences were statistically significant (P<0.05). Conclusion: Mesalazine can reduce the serum levels of IL-10, CRP and TNF-α in patients with ulcerative colitis, which is effective and safety for clinical treatment. [ABSTRACT FROM AUTHOR]

Obejective: To investigate the effects of ezetimibe and atorvastatin on the oxidative stress and blood lipid levels in patients with coronary heart disease and its clinical efficacy. Methods: 144 cases with coronary heart disease who were treated in our hospital from August 2013 to August 2016 were selected and randomly divided into the control group and the study group, with 72 cases in each group. The patients in the control group were treated with atorvastatin and nitroglycerin, while the patients in the study group were treated with atorvastatin and ezetimibe. Then the serum levels of peroxidase (MPO), propylene glycol (MDA), superoxide dismutase (SOD), total cholesterol (TC), glycerin three greases (TG), low density lipoprotein (LDL-C) and high density lipoprotein (HDL-C), heart functions and clinical curative effect between the two groups were observed and compared before and after the treatment. Results: The total clinical effective rate in the study group was 87.5%, which was higher than 76.4%in the control group, and the difference was statistically significant (P<0.05); After the treatment, the serum levels of MDA and MPO decreased in the two groups, while the SOD increased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the serum levels of MDA and MPO were lower in the study group, and the SOD was higher, and the differences were statistically significant (P<0.05); After treatment, the serum levels of HDL-C increased in the two groups, while the levels of LDL-C, TC and TG decreased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the serum levels of HDL-C was higher in the study group, and the levels of LDL-C, TC and TG were lower, and the differences were statistically significant (P<0.05); Compared with before treatment, the LVEDD and LVESD decreased in the two groups after the treatment, while the LVEF increased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the LVEDD and LVESD were lower in the study group, and the LVEF was higher, and the differences were statistically significant (P<0.05). Conclusions: Ezetimibe and atorvastatin have obvious clinical efficacy on the treatment of coronary heart disease, which can reduce the blood lipid levels of patients, and improve the oxidative stress and heart function, and it is worthy of clinical application. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effect of ipratropium bromide combined with budesonide on the changes of MDA, SOD and GSH-Px levels and pulmonary function of patients with chronic obstructive pulmonary emphysema and type II respiratory failure. Methods: 92 patients with chronic obstructive pulmonary emphysema and type II respiratory failure were selected and randomly divided into the control group and the experiment group, with 46 cases in each group. The patients in the control group were treated with the conventional method, while the patients in the experiment group were treated with the ipratropium bromide and budesonide inhalation besides the conventional method. Then the levels of SOD, GSH-Px and MDA, the pulmonary function and blood gas indexes were observed and compared before and after the treatment. Results: After the treatment, the levels of SOD, GSH-Px, FEV1, VC and Pa O2 in the two groups were higher than before, and the levels of MDA, RV, TLC and Pa CO2 were lower with statistically significant differences (P<0.05). Compared with the control group, the levels of SOD, GSH-Px, FEV1, VC and Pa O2 in the experiment group were higher, and the levels of MDA, RV, TLC and Pa CO2 were lower with statistically significant differences (P<0.05). Conclusion: The ipratropium bromide and budesonide can improve the pulmonary function parameters, blood gas indexes and MDA, SOD and GSH PX levels of patients with COPD and type II respiratory failure, and to strengthen the function of antioxidant system. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effect of benthiactzine on the products of oxidative stress and cellular immune factors of patients with organophosphate poisoning combined with respiratory failure. Methods: 84 patients who were diagnosed with organophosphate poisoning and respiratory failure in our hospital were selected and randomly divided into the control group and the experiment group. The patients in the control group were treated with atropine, while the patients in the experiment group were treated with benthiactzine. Then the level changes of superoxide dismutase (SOD), malondialdehyde (MDA) and glutathiose (GSH), CD4+, CD8+, CD4+/CD8+, and (NK) ( CD16+CD56+) levels were measured before and after the treatment. Results: Compared with before, the levels of SOD and GSH were higher and the MDA was lower in the two groups after the treatmet with statistically significant differences (P<0.05). Compared with control group, the levels of SOD and GSH were higher and the MDA was lower in the experiment group after the treatment, and the differences were statistically significant (P<0.05). Compared with before, the levels of CD4+and CD8+were higher, and the levels of CD4+/CD8+and (NK)(CD16+CD56+) were lower in the two groups after the treatment, and the differences were statistically significant (P<0.05). Compared with the control group, the levels of CD4+and CD8+were higher,and the levels of CD4+/CD8+and (NK) (CD16+CD56+) were lower in the experiment group after the treatment, and the differences were statistically significant (P<0.05). Conclusion: Benthiactzine could significantly improve the products of oxidative stress and cellular immune factors of patients with organophosphate poisoning and respiratory failure, which is worthy of clinical application. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effect of the addie injection combined with thalidomide on the changes of APRIL, β 2-m and TPO for elderly patients with the multiple myeloma. Methods: 80 elderly patients with multiple myeloma were selected and according to the different treatment methods, the patients were divided into the control group and the experiment group. The patients in the control group were treated with vincristine, epinephrine hydrochloride and dexamethasone, while the patients in the experiment group were treated with addie injection and thalidomide. Then the changes of bone marrow plasma cells, M protein, hemoglobin, immune function,renal function and the levels of APRIL, β 2-m and TPO in the two groups were observed and compared before and after the treatment. Results: Compared with the control group, the immune function and renal function of patients in the experiment group obviously improve and the activity of tumor cells inhibited, and the differences were statistically significant (P<0.05). Compared with control group, the bone marrow plasma cells, M protein, creatinine and the urea nitrogen levels were lower in the experiment group, the hemoglobin and CD4+/CD8+ratio were higher and the levels of APRIL, β 2-m and TPO were lower, and the differences were statistically significant (P<0.05). Conclusion: Aidi injection combined with thalidomide can reduce the activity of tumor cells and enhance the immune function of patients. [ABSTRACT FROM AUTHOR]